GeneOne Life Science

At a glance

GeneOne Life Science filed 136 disclosures in the last 12 months, including 8 5% holder, 4 issuance and 2 insider. The most recent key filing was on Aug 5.

Revenue for 2025 was ₩23B, down 35.5% on 2024. It made an operating loss of ₩44B. Debt was 191% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩4.6B and operating loss of ₩15.2B.

The 2025 annual report lists 52 employees with an average tenure of 7.7 years and average pay of ₩70.5M, #687 of 2,191 listed companies by average pay. Its 6 directors and auditors were paid ₩26M each on average. It paid no cash dividend for 2025. 박영근 and related parties held 8.92% at year end.

Of 5 recent 5%+ holder reports, 1 raised and 2 cut a stake; the largest stake reported was 12.42% on Jun 29.

From the 2025 annual report

Staff: 52 (32 men, 20 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩3.7B. Directors and auditors: 6, paid ₩154M in total.

No cash dividend was paid for 2025.

Largest shareholder

박영근 holds 7.03%; with 7 related parties the group holds 8.92% of common shares at year end (from 10.35% at the start of the year).

Auditor: 대주회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports